NLS Pharmaceutics Ltd (NLSP)
3.365
+0.08
(+2.28%)
USD |
NASDAQ |
Nov 21, 16:00
3.17
-0.20
(-5.79%)
Pre-Market: 20:00
NLS Pharmaceutics Total Liabilities (Quarterly): 10.46M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 10.46M |
| June 30, 2024 | 10.46M |
| December 31, 2023 | 10.68M |
| June 30, 2023 | 6.557M |
| June 30, 2023 | 6.557M |
| December 31, 2022 | 5.996M |
| June 30, 2022 | 6.100M |
| June 30, 2022 | 6.100M |
| December 31, 2021 | 5.222M |
| Date | Value |
|---|---|
| June 30, 2021 | 4.020M |
| June 30, 2021 | 4.020M |
| December 31, 2020 | 10.20M |
| June 30, 2020 | 7.974M |
| June 30, 2020 | 7.974M |
| December 31, 2019 | 6.867M |
| June 30, 2019 | 5.571M |
| June 30, 2019 | 5.571M |
| December 31, 2018 | 8.959M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
4.020M
Minimum
Jun 2021
10.68M
Maximum
Dec 2023
7.279M
Average
6.557M
Median
Jun 2023
Total Liabilities (Quarterly) Benchmarks
| AC Immune SA | 135.61M |
| CRISPR Therapeutics AG | 316.47M |
| Addex Therapeutics Ltd | 1.164M |
| Molecular Partners AG | 18.34M |
| MoonLake Immunotherapeutics | 22.71M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.194M |
| Shareholders Equity (Quarterly) | -9.268M |